Article
Efficacy of Kan Jang® in Patients with Mild COVID-19: a Randomized, Quadruple-Blind, Placebo-Controlled Trial
2023-08-01
Abstract excerpt
<h4>Background: </h4> and aim. The study aimed to assess the efficacy of the treatment of Kan Jang®, a fixed combination of Andrographis paniculata (Burm. F.) Wall. ex. Nees and Eleutherococcus senticosus (Rupr. & Maxim.) Maxim in patients with mild symptoms of COVID-19. Methods. One hundred forty patients received six capsules of Kan Jang® (n = 68, daily dose of andrographolides – 90 mg) or placebo (n=72) and...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a47e2527-436f-56a7-8b12-27476454b6a6
- DOI
- 10.20944/preprints202307.2113.v1
